Safest Dose Of Retatrutide (NEXT-LEVEL Appetite Suppression) Insulin Sensitivity, Fat Loss Deep-Dive

Understanding the Implications of Retroutite

Clinical Trials and Body Composition Concerns

• The clinical trials for Retroutite do not assess changes in body composition, specifically regarding fat mass versus muscle mass reduction. They only report total body weight changes without clarifying the source of this weight loss.

• A reported 25-30% reduction in body weight after 48 weeks on a specific dosage is promising, but it remains unclear whether this reduction is from fat mass or other factors like muscle or intestinal mass.

Liver Fat Reduction and NAFLD

• Significant reductions in liver fat content were observed with various dosages of Retroutite, indicating a dose-dependent effect. This was particularly noted in studies related to non-alcoholic fatty liver disease (NAFLD), which is now being rebranded as metabolic dysfunction-associated steatotic liver disease (MASLD).

Extrapolation from Animal Studies

• The discussion includes dubious extrapolations from animal studies involving a similar compound developed by Eli Lilly that targets glucagon receptors. One study published in January 2025 showed dose-dependent effects on body weight and composition.

Effects on Blood Glucose and Muscle Mass

• An animal study indicated that higher doses of the glucagon receptor agonist led to decreased body weight, fat mass, and muscle mass while also affecting blood glucose levels. However, results varied significantly across different parameters.

Dosing Protocol Considerations

• The dosing range for LY 3324954 was between 1 nanomole to 300 nanomoles per kilogram; however, its molecular weight remains unknown. This complicates any attempts at translating these findings into human equivalent dosages.

Unique Characteristics of Retroutite

Mechanism of Action

• Retroutite primarily activates the GLP-1 receptor with lower potency compared to endogenous GLP-1 but has greater efficacy on GIP receptors. This suggests that its mechanism may differ significantly from traditional treatments targeting multiple pathways.

Energy Expenditure Insights

• It appears that retroutite may enhance overall energy expenditure, potentially preventing metabolic adaptation during prolonged caloric restriction based on in vitro studies.

Resistance to Enzyme Breakdown

Retroutite: A Potential Game Changer in Appetite Suppression and Weight Loss

Mechanism of Action and Effects on Appetite

• Retroutite has been shown to reduce the required dose for effective appetite suppression while promoting fat loss, based on studies involving both human subjects and animal models.

• It induces weight loss by reducing gastric emptying, intestinal transit, and waist circumference, alongside improving insulin sensitivity and lipid profiles.

Impact on Metabolic Health

• Retroutite exhibits insulinotropic effects that enhance glucose tolerance, lowering levels of glucose, triglycerides, total cholesterol, LDL, amino acids, fasting insulin, glucagon, and hemoglobin A1C in the bloodstream.

• In individuals with type 2 diabetes mellitus (T2DM), retroutite increases fasting insulin levels which aids in better glucose homeostasis; however, it lowers fasting insulin in healthy individuals.

Cardiovascular Benefits

• The compound raises resting heart rates by 6.7 to 12 beats per minute compared to other incretin-based medications but may cause mild to moderate cardiac arrhythmias through blood pressure modulation.

• Retroutite shows promise as a treatment for non-alcoholic fatty liver disease (NAFLD), metabolic dysfunction-associated steatotic liver disease (MASLD), and non-alcoholic steatohepatitis (NASH).

Broader Therapeutic Applications

• It may also serve as a treatment for lifestyle-induced cardiovascular diseases and chronic kidney disease due to its appetite control capabilities.

• There is potential for retroutite to address binge eating disorders and even addiction related to dopaminergic pathways; however, scientific evidence remains limited.

Cancer Treatment Potential

• Retroutite could be beneficial in treating triple-negative breast cancer associated with obesity by downregulating hexamine biosynthesis pathways and enhancing chemotherapy efficacy.

Cost Comparison with Bariatric Surgery

• While bariatric surgery costs between $17,000 to $26,000 in the U.S., retroutite might offer similar appetite suppression benefits at an estimated monthly cost of $800 to $1,150 without insurance coverage.

Long-term Efficacy Compared to Surgery

• Users might experience up to 2.5 years of appetite suppression with retroutite compared to bariatric surgery's immediate but potentially less sustainable results regarding appetite control.

Personal Experiences with Appetite Control

• Individuals undergoing prolonged cutting phases often face extreme hunger despite reduced stomach size; retroutite offers a solution by minimizing cravings while still allowing for satiation after small meals.

Limitations of Current Research

Effects of GLP-1 Receptor Agonists on Weight Loss

Overview of Dosages and Efficacy

• The discussion begins with an analysis of maximum dosages for various GLP-1 receptor agonists and their efficacy in weight loss, emphasizing the need for specific milligram amounts to achieve expected results.

Raw Data Presentation

• The speaker presents raw data on body weight reduction from GLP-1 receptor agonists, noting that some studies lack baseline starting weights, leading to net kilograms or pounds lost being reported instead of percentage reductions.

Body Fat and Waist Circumference Reduction

• Information is provided regarding body fat reduction associated with glucagon receptor agonists, highlighting that only a few medications like lag glutide and semiglutide have known percentages.

• Waist circumference reductions are discussed, showing available data in centimeters or inches for better understanding.

Liver Fat and Cholesterol Reduction Insights

• The effects of GLP-1 receptor agonists on liver fat reduction are presented, including both relative and absolute reductions expressed as percentages.

• Total cholesterol reduction is also covered, typically measured in milligrams per deciliter or millimoles per liter.

Hemoglobin A1C Levels Analysis

• Hemoglobin A1C levels are examined as they relate to type 2 diabetes management; most GLP-1 receptor agonists show significant reductions over time.

Expected Outcomes from 3 mg Retroite Weekly

Body Weight Reduction Expectations

• Using 3 mg retroite weekly is projected to yield approximately a 12.08% body weight reduction; dosage ranges for other GLP-1 receptor agonists are provided for similar outcomes.

Waist Circumference Reduction Projections

• For waist circumference, a reduction of about 10 cm (4 inches) is anticipated with the same dosage of retroite; comparable doses for other medications are listed.

Liver Fat Reduction Comparisons

• Relative liver fat reduction expectations from 3 mg retroite weekly suggest a decrease of around 59.1%, with corresponding dosages for other GLP-1 receptor agonists displayed.

Cholesterol and Hemoglobin A1C Reductions

• Total cholesterol should reduce by approximately 5.2% when using 3 mg retroite weekly; relevant dosages for achieving this effect with other medications are included.

Comparative Dosing Among Various GLP-1 Receptor Agonists

Dosing Protocol Discrepancies

• A comparison highlights how different dosing protocols exist among various GLP-1 receptor agonists:

• Retroite's subcutaneous administration contrasts sharply with oral forms like exenatide.

Dosage Comparisons and Cost Savings in GLP-1 Agonists

Switching Between Medications

• The mean administration dose for retreatide is 3 mg subcutaneously weekly, compared to 7.5 mg for tzepidite, indicating a significant cost-saving opportunity when switching medications.

• Other medications mentioned include migodite (2.4 mg), massite (5.3 mg), and ephenopgutide (8.9 mg), each with varying weekly dosages that can impact treatment decisions.

Administration Insights

• For optimal results, retreatide should ideally be administered as 1 mg shots on Monday, Wednesday, and Friday to achieve comparable effects to higher doses of other medications.

• The speaker acknowledges potential errors in dosage calculations due to the complexity of the data but emphasizes the importance of sharing personal experiences regarding medication switches.

Patient Experiences and Anecdotal Evidence

• Viewers are encouraged to share their experiences transitioning from exinatite or llutide to retreatide, particularly regarding blood work results and overall health impacts.

• The speaker reflects on their own history with these medications, noting fluctuations in weight after discontinuation.

Potential Side Effects of GLP-1 Receptor Agonists

Kidney Function Concerns

• There are documented risks associated with kidney function impairment among laglutide, semiglutide, and retreatide; while some may improve kidney function, others have been linked to acute kidney injury.

• Dehydration from gastrointestinal upset is noted as a contributing factor to increased serum creatinine levels during treatment.

Liver Function Implications

• Although generally not toxic to the liver, certain GLP-1 receptor agonists like exynetite and laglutide can elevate liver enzymes and have rare associations with autoimmune hepatitis.

Pancreatitis Risks

• A potential link between various GLP-1 receptor agonists (including exynotide and laglutide) and pancreatitis or pancreatic cancer has been suggested but lacks conclusive scientific evidence.

Gastrointestinal Adverse Events

Common Side Effects

• Gastrointestinal issues such as nausea, vomiting, diarrhea, bloating, and acid reflux are common across multiple GLP-1 receptor agonists; these side effects tend to be dose-dependent.

Tolerance Development

• Patients often develop tolerance over time; however, if doses need escalation due to loss of satiation effects, side effects may re-emerge.

Cardiovascular Effects

Heart Rate Variability

• Elevated resting heart rates have been observed with several GLP-1 receptor agonists including exynotide and semiglutide; specific arrhythmias have also been reported.

Clinical Observations

Semaglutide and Retrorutide: Insights on Cardiac Effects and Neurotransmitter Modulation

Cardiac Effects of GLP-1 Receptor Agonists

• Semaglutide is linked to an increased resting heart rate, while Retrorutide has been associated with supraventricular arrhythmias and cardiac conduction disorders during clinical trials.

• The side effects observed were dose-dependent but not classified as serious compared to other GLP-1 receptor agonists, which also report similar cardiac issues.

Neurotransmitter Modulation in Weight Management

• Exenatide, Liraglutide, and Semaglutide have shown potential for neurotransmitter modulation; however, evidence remains limited.

• Exenatide may have neuroprotective effects in Parkinson's disease by influencing dopamine cell survival, though direct modulation of dopamine levels is not well documented.

Appetite Regulation Mechanisms

• Liraglutide reduces the expression of hypothalamic 5HT2A receptors involved in appetite regulation; however, this finding is based on animal models and lacks human validation.

• While there are theoretical potentials for Semaglutide to influence serotonin and dopamine levels, studies indicate it does not significantly affect the efficacy of selective serotonin reuptake inhibitors in depressed patients.

Safety Concerns with Retrorutide

• Although Retrorutide appears safer than other FDA-approved GLP-1 receptor agonists currently used for obesity or type 2 diabetes, concerns about pancreatitis and cancer risks may arise once it enters the market.

• Clinical trials for Retrorutide are set to conclude by 2029; thus, long-term safety data will take years to accumulate post-market introduction.

Dosing Protocol Recommendations

• Caution is advised when using weekly dosages of GLP-1 receptor agonists. Microdosing (e.g., three times weekly at low doses) may enhance diet adherence during cutting phases.

• Clinical trial dosages suggest that lower doses (0.25 mg - 1.66 mg subcutaneously three times a week) can effectively manage appetite without severe side effects compared to higher doses (over 12 mg weekly).

Managing Side Effects During Treatment

• Starting with lower doses allows gradual adaptation; gastrointestinal side effects like nausea or vomiting can occur if high doses are administered too quickly.

Tepidite vs. Retrotride: A Comparative Analysis

Appetite Suppression and Cost-Effectiveness

• Users prefer tepidite over retrotride for better appetite suppression on a milligram-for-milligram basis, while tepidite is approximately 30% cheaper.

• Despite the cost-effectiveness of tepidite, some users report improved appetite control with retrotride during the offseason.

Insulin Sensitivity and Non-Alcoholic Fatty Liver Disease

• Retrotride may help sustain insulin sensitivity and prevent non-alcoholic fatty liver disease through caloric restriction stimulated by its appetite-suppressing effects.

• The speaker plans to test retrotride at low doses during their next offseason to evaluate its impact on insulin sensitivity and liver health.

Anecdotal Evidence in Bodybuilding Community

• Many bodybuilders report enhanced glucose homeostasis when using retrotride at low effective doses, although scientific evidence remains inconclusive.

• There are anecdotal claims that including retrotride in supplementation protocols leads to better muscle gains compared to previous offseasons without it.

Potential Side Effects: Flatness and Glycogen Storage

• Some users claim that both retrotride and tepidite can cause a feeling of flatness due to appetite suppression affecting carbohydrate intake.

• Activation of glucagon receptors may lead to gluconeogenesis but does not affect glycogen stored in skeletal muscle; thus, flatness could indicate issues with diet or electrolytes.

Fat Loss Benefits of Retrotride

• Retrotride is noted for its effectiveness in fat loss due to appetite suppression and mobilization of fatty acids, distinguishing it from other GLP-1 receptor agonists.

Exploring the Role of GLP-1 Receptor Agonists in Addiction Management

The Potential of Retroite and Other GLP-1 Receptor Agonists

• Discussion on how retroite or GLP-1 receptor agonists may assist in managing addiction, although they may not be as effective as other treatments like cerebralin.

• Emphasis on the effectiveness of these medications for food addiction, noting that symptoms may return once treatment is discontinued.

Personal Experiences with Food Addiction

• The speaker shares personal struggles with food addiction, highlighting challenges in appetite control and weight management when off medication.

• Reference to clinical trials indicating that maintaining a consistent dose of retroite can help manage obesity and type 2 diabetes effectively over time.

Long-term Use and Dosage Considerations

• Acknowledgment that ongoing use of retroite might be necessary for those overcoming addictions, suggesting potential long-term dependency on the medication.

• Encouragement for audience feedback regarding their experiences with retroite, including side effects and its effectiveness during fat loss phases.

Health Monitoring During Self-experimentation

• Advice to conduct blood work through Mer Health while experimenting with medications to ensure health safety during self-experimentation.

• Offer for consultation services to help individuals develop personalized protocols based on their health needs and experiences with appetite suppression medications.

Conclusion: Future Considerations